Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5

Patent metadata

Field	Value
Publication number	US-9926379-B2
Application number	US-201414231933-A
Country	US
Kind code	B2
Filing date	Apr 1, 2014
Priority date	Apr 3, 2013
Publication date	Mar 27, 2018
Grant date	Mar 27, 2018

Abstract

The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

First claim

We claim:

1. A bispecific antibody that binds to death receptor 5 (DR5) and Fibroblast Activation Protein (FAP), comprising at least one antigen binding site specific for DR5 comprising
(a) a heavy chain CDR1 of SEQ ID NO.:1;
(b) a heavy chain CDR2 of SEQ ID NO.:2;
(c) a heavy chain CDR3 of SEQ ID NO.:3;
(d) a light chain CDR1 of SEQ ID NO.:4;
(e) a light chain CDR2 of SEQ ID NO.:5; and
(f) a light chain CDR3 of SEQ ID NO.:6
and at least one antigen binding site specific for FAP comprising
(a) a heavy chain CDR1 of SEQ ID NO.:9;
(b) a heavy chain CDR2 of SEQ ID NO.:10;
(c) a heavy chain CDR3 of SEQ ID NO.:11;
(d) a light chain CDR1 of SEQ ID NO.:12;
(e) a light chain CDR2 of SEQ ID NO.:13; and
(f) a light chain CDR3 of SEQ ID NO.:14.

2. The bispecific antibody of claim 1 , wherein the antigen binding site specific for DR5 comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO.:7 and a variable light chain comprising an amino acid sequence of SEQ ID NO.:8; and
the antigen binding site specific for FAP comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO.:15 and a light chain variable region comprising an amino acid sequence of SEQ ID NO.:16.

3. The bispecific antibody of claim 1 , wherein the antibody is humanized.

4. The bispecific antibody of claim 1 , comprising an Fc domain, at least one Fab fragment comprising the antigen binding site specific for DR5, and at least one Fab fragment comprising the antigen binding site specific for FAP.

5. The bispecific antibody of claim 4 , wherein at least one of the Fab fragments is connected to the first or second subunit of the Fc domain via the light chain (VLCL) and at least one Fab fragment is connected to the first or second subunit of the Fc domain via the heavy chain (VHCH1).

6. The bispecific antibody of claim 4 , comprising
a) an Fc domain,
b) two Fab fragments comprising an antigen binding site specific for DR5,
wherein said Fab fragments are connected at the C-terminus of the constant light chain (CL) to the first or second subunit of the Fc domain,
c) two Fab fragments comprising the antigen binding site specific for FAP, wherein the two Fab fragments are connected at the C-terminus of the constant heavy chain (CH1) to the first or second subunit of the Fc domain.

7. The bispecific antibody of claim 4 , comprising
a) an Fc domain,
b) two Fab fragments comprising an antigen binding site specific for DR5,
wherein said Fab fragments are connected at the C-terminus of the constant heavy chain (CH1) to the first or second subunit of the Fc domain,
c) two Fab fragments comprising the antigen binding site specific for FAP, wherein the two Fab fragments are connected at the C-terminus of the constant light chain (CL) to the first or second subunit of the Fc domain.

8. The bispecific antibody of claim 4 , wherein at least one of the Fab fragments are is connected to the Fc domain via a peptide linker.

9. The bispecific antibody of claim 4 , wherein the Fc domain comprises one or more amino acid substitutions that reduce binding to an Fc receptor and/or effector function.

10. The bispecific antibody of claim 9 , wherein the Fc domain is a human IgG Fc domain comprising one or more amino acid substitutions selected from the group of L234, L235, and P329 according to EU numbering.

11. The bispecific antibody of claim 10 , wherein each subunit of the Fc domain comprises three amino acid substitutions that reduce binding to an activating or inhibitory Fc receptor and/or effector function wherein said amino acid substitutions are L234A, L235A and P329G.

12. The bispecific antibody of claim 4 , wherein the Fc domain comprises a first dimerization module and a second dimerization module allowing a heterodimerization of the two heavy chains of the Fc domain of the antibody.

13. The bispecific antibody of claim 12 , wherein the first dimerization module comprises knobs and the second dimerization module comprises holes according to the knobs into holes strategy.

14. The bispecific antibody of claim 1 , wherein the antibody comprises an Fc domain, at least one Fab fragment comprising the antigen binding site specific for DR5, and at least one Fab fragment comprising the antigen binding site specific for FAP, wherein the at least one Fab fragment comprising the antigen binding site specific for DR5 or the at least one Fab fragment comprising the antigen binding site specific for FAP is a crossover Fab fragment.

15. The bispecific antibody of claim 14 , comprising two Fab fragments comprising each an antigen binding site specific for DR5, and two Fab fragments comprising each an antigen binding site specific for FAP.

16. The bispecific antibody of claim 15 , wherein the bispecific antibody is bivalent both for DR5 and FAP.

17. The bispecific antibody of claim 14 , comprising two Fab fragments comprising each an antigen site specific for DR5, and one Fab fragment comprising an antigen binding site specific for FAP.

18. The bispecific antibody of claim 17 , wherein the bispecific antibody is bivalent for DR5 and monovalent for FAP.

19. The bispecific antibody of claim 17 , comprising one additional Fab fragment comprising an antigen binding site specific for DR5.

20. The bispecific antibody of claim 19 , wherein the bispecific antibody is trivalent for DR5 and monovalent for FAP.

21. The bispecific antibody of claim 14 , comprising one Fab fragment comprising an antigen binding site specific for DR5, and one Fab fragment comprising an antigen binding site specific for FAP.

22. The bispecific antibody of claim 21 , wherein the bispecific antibody is monovalent for DR5 and monovalent for FAP.

23. The bispecific antibody of claim 14 , wherein the at least one Fab fragment comprising the antigen binding site specific for FAP is a crossover Fab fragment.

24. The bispecific antibody of claim 1 , wherein the bispecific antibody induces apoptosis by cross-linking DR5.

25. A pharmaceutical composition comprising the bispecific antibody of claim 24 and a pharmaceutically acceptable carrier.

26. An antibody that specifically binds to DR5, comprising
(a) a heavy chain CDR1 of SEQ ID NO.:1;
(b) a heavy chain CDR2 of SEQ ID NO.:2;
(c) a heavy chain CDR3 of SEQ ID NO.:3;
(d) a light chain CDR1 of SEQ ID NO.:4;
(e) a light chain CDR2 of SEQ ID NO.:5; and
(f) a light chain CDR3 of SEQ ID NO.:6.

27. The antibody of claim 26 , comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO.:7 and a variable light chain comprising an amino acid sequence of SEQ ID NO.:8.

28. A composition comprising the antibody of claim 26 or 27 and a pharmaceutically acceptable carrier.

Assignees

• Roche Glycart Ag

Inventors

• Bruenker Peter
• Daouti Sherif
• Feng Ningping
• Ferrara Koller Claudia
• Georges Guy
• Grau-Richards Sandra
• Hosse Ralf
• Klein Christian
• Koenig Maximiliane
• Moelleken Joerg
• Moessner Ekkehard
• Niu Huifeng
• Packman Kathryn E
• Runza Valeria
• Seeber Stefan
• Umana Pablo
• Waldhauer Inja
• Wang Huisheng
• Weiser Barbara

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07K2317/35

  Valency · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title